Safety of regadenoson in patients with severe chronic obstructive pulmonary disease

详细信息    查看全文

• 作者：C. Salgado-Garcia^a ; ^{carlosd.salgado.sspa@juntadeandalucia.es" class="auth_mail" title="E-mail the corresponding author} ; A. Jimenez-Heffernan^a ; C. Ramos-Font^a ; J. Lopez-Martin^a ; E. Sanchez-de-Mora^a ; T. Aroui^a ; R. Lopez-Aguilar^b ; F. Rivera-de-los-Santos^c ; C. Ruiz-Frutos^d
• 关键词：Regadenoson ; Safety ; Adverse events ; Severe chronic obstructive pulmonary disease ; Myocardial perfusion imaging
• 刊名：Revista Española de Medicina Nuclear e Imagen Molecular
• 出版年：2016
• 出版时间：September-October 2016
• 年：2016
• 卷：35
• 期：5
• 页码：283-286
• 全文大小：741 K

文摘

To assess the safety of regadenoson, a selective agonist of A_2A adenosine receptors, combined with low-level exercise in subjects with severe chronic obstructive pulmonary disease (COPD), referred for myocardial perfusion imaging (MPI).

Methods

We studied prospectively 12 male patients with severe COPD. Stress was 4 min of low-level exercise with bolus injection of regadenoson (0.4 mg) at 1.5 min, followed by ^99mTc-MPI agent injection. Demographics, medical history, lung medications, adverse events, oxygen saturation (SatO₂), MPI findings for coronary artery disease (CAD), and changes in systolic blood pressure (SBP), and heart rate (HR) were registered.

Results

The observed adverse event profile of regadenoson was similar to that of patients with mild–moderate COPD. There was no clinical exacerbation of COPD. Adverse events were self-limiting: dyspnea (33.3%), fatigue (25.0%), chest pain, headache (16.7%, respectively), and gastrointestinal discomfort, dry mouth, flushing, feeling hot and dizziness (8.3%, respectively). 25.0% of patients did not report any symptoms. We observed significant increases in SBP and HR from baseline (142.6 mmHg ± 22.3 vs 152.5 mmHg ± 18.5, and 80 b.p.m. ± 18 vs 105 b.p.m. ± 22, respectively; p < 0.05).

Conclusions

Regadenoson combined with low-level exercise is safe and well tolerated in stable patients with severe COPD undergoing MPI.